All sponsors

TG Therapeutics, Inc. $TGTX

Clinical trial pipeline · active industry-sponsored Phase 1/2 to Phase 3 trials · updated 2026-11-13
ACTIVE TRIALS7
PHASE 3 / 2-34
RECRUITING5
READOUTS ≤12 MONTHS2
Open TG Therapeutics, Inc. on the live radar map → 📅 $TGTX readout calendar (.ics)
TRIALPHASESTATUSCONDITIONNPRIMARY COMPLETION
Ublituximab
NCT07211633
P3Active, not recruitingRelapsing Multiple Sclerosis3602026-10-31 (-2 mo)
ENHANCE
NCT05877963
P3RecruitingRelapsing Multiple Sclerosis8002027-01-21 (+20 mo)
Ublituximab
NCT07503873
P2RecruitingMultiple Sclerosis3502027-07-31
Ublituximab
NCT07673744
P2RecruitingMyasthenia Gravis1202028-07-01
Ublituximab
NCT07680946
P2RecruitingSchizophrenia602028-12-12
Ublituximab
NCT07220252
P2/3RecruitingRelapsing Multiple Sclerosis2402030-01-01
Ublituximab
NCT04130997
P3Active, not recruitingRelapsing Multiple Sclerosis (RMS)11002032-05-31 (+104 mo)